Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: Effective monitoring of CMV infection by quantitative analysis of CMV mRNA

Bone Marrow Transplantation

Volumn 27, Issue 11, 2001, Pages 1141-1145

  Ohta, H ^a   Matsuda, Y ^a   Tokimasa, S ^a   Sawada, A ^a   Kim, J Y ^a   Sashihara, J ^a   Amo, K ^a   Miyagawa, H ^a   Tanaka Taya, K ^a   Yamamoto, S ^a   Tano, Y ^a   Aono, T ^b   Yamanishi, K ^a   Okada, S ^a   Hara, J ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Toyobo Research Inst   (Japan)

Author keywords

Cytomegalovirus; Foscarnet; Ganciclovir; Hematopoietic stem cell transplantation; NASBA; Resistance

Indexed keywords

FOSCARNET; GANCICLOVIR; MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ACUTE LEUKEMIA; ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DONOR; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE AMPLIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INFANT; MONITORING; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RETINITIS; TREATMENT OUTCOME; VIRUS REPLICATION;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; DRUG RESISTANCE, VIRAL; FEMALE; FOSCARNET; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL;

EID: 0034960650     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703055     Document Type: Article

References (19)

1. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
2. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS
3. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation
4. Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction
5. Antiviral drugs
6. Clinical use of ganciclovir for cytomegalovirus infection and the development of drug resistance
7. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection
8. Monitoring of human cytomegalovirus infections in pediatric bone marrow transplant recipients by nucleic acid sequence-based amplification
9. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients
10. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals
11. Cytomegalovirus retinitis after transplantation of positively selected CD34+ cells from HLA-mismatched donors
12. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease
13. Resistance to antivirals in human cytomegalovirus: Mechanisms and clinical significance
14. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151
15. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis
16. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation
17. The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports
18. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation
19. Monitoring of CMV infection: A comparison of PCR from whole blood, plasma-PCR. pp65-antigenemia and virus culture in patients after bone marrow transplantation